Abstract
This article describes recent advances in the development of subtype-selective, noncompetitive modulators of metabotropic glutamate receptor subtype 1 (mGluR1). mGluR1 plays an important role in modulating synaptic transmission and neuronal excitability via intracellular signal transduction pathways and has been implicated in a number of CNS disorders. Allosteric modulation of mGluR1 by potentiation and antagonism occurs through binding to the seven transmembrane domain. In addition to blocking agonist-dependent responses, many of the antagonists also show inverseagonist activity by blocking constitutive receptor activity. Highly potent and selective mGluR1 radioligands have been used to evaluate receptor binding in vivo and in vitro. Some of these novel agents have demonstrated high levels of CNS exposure and receptor occupancy in vivo, as well as efficacy in a number of preclinical models of neurological disorders.
Keywords: mglur review, metabotropic glutamate receptor subtype, selective allosteric modulators, potentiator
Current Topics in Medicinal Chemistry
Title: Subtype-Selective Noncompetitive Modulators of Metabotropic Glutamate Receptor Subtype 1 (mGluR1)
Volume: 5 Issue: 9
Author(s): Mark E. Layton
Affiliation:
Keywords: mglur review, metabotropic glutamate receptor subtype, selective allosteric modulators, potentiator
Abstract: This article describes recent advances in the development of subtype-selective, noncompetitive modulators of metabotropic glutamate receptor subtype 1 (mGluR1). mGluR1 plays an important role in modulating synaptic transmission and neuronal excitability via intracellular signal transduction pathways and has been implicated in a number of CNS disorders. Allosteric modulation of mGluR1 by potentiation and antagonism occurs through binding to the seven transmembrane domain. In addition to blocking agonist-dependent responses, many of the antagonists also show inverseagonist activity by blocking constitutive receptor activity. Highly potent and selective mGluR1 radioligands have been used to evaluate receptor binding in vivo and in vitro. Some of these novel agents have demonstrated high levels of CNS exposure and receptor occupancy in vivo, as well as efficacy in a number of preclinical models of neurological disorders.
Export Options
About this article
Cite this article as:
Layton E. Mark, Subtype-Selective Noncompetitive Modulators of Metabotropic Glutamate Receptor Subtype 1 (mGluR1), Current Topics in Medicinal Chemistry 2005; 5 (9) . https://dx.doi.org/10.2174/1568026054750245
DOI https://dx.doi.org/10.2174/1568026054750245 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Prophylactic Use of Antiepileptic Drugs in Patients Scheduled for Neurosurgery
Current Pharmaceutical Design Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives
Central Nervous System Agents in Medicinal Chemistry An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets The Therapeutic Potential of Neural Stem Cells in Traumatic Brain Injuries
Current Signal Transduction Therapy Anxiolytic-Like Effects of 7H-Benzo[e]perimidin-7-One Derivatives through Elevated Plus-Maze Test in Mice
Current Topics in Medicinal Chemistry Z-Acrylonitrile Derivatives: Improved Synthesis, X-ray Structure, and Interaction with Human Serum Albumin
Current Organic Synthesis Non-Antidepressant Pharmacologic Long-Term Treatment of Panic Disorder
Current Clinical Pharmacology Recent Progress in Syntheses and Biological Activities of Kainic Acid and its Derivatives
Current Organic Chemistry Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Recent Advances and Patents on Nanoscale Systems and Triggerable Drug Delivery in Medical Devices
Recent Patents on Biomedical Engineering (Discontinued) Anxiety: A Systematic Review of Neurobiology, Traditional Pharmaceuticals and Novel Alternatives from Medicinal Plants
CNS & Neurological Disorders - Drug Targets The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers
Current Drug Targets Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?
Current Medicinal Chemistry Mood Disorders in Elderly Population: Neurostimulative Treatment Possibilities
Recent Patents on CNS Drug Discovery (Discontinued) Current Development in Encapsulated Cell Therapy for Degenerative Retinopathies
Current Tissue Engineering (Discontinued) Functional Characterisation of Homomeric Ionotropic Glutamate Receptors GluR1-GluR6 in a Fluorescence-Based High Throughput Screening Assay
Combinatorial Chemistry & High Throughput Screening CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective
Current Stem Cell Research & Therapy Video Game Addiction: Past, Present and Future
Current Psychiatry Reviews